Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

ROSEMONT, Ill. (April 29, 2025) — A recent survey of more than 1,000 U.S. adults showed that nearly all Americans believe sun protection is important, with 1 in 4 citing the influence of a ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.

Crepey skin, characterized by its thin, wrinkled texture resembling crepe paper, is a common concern as we age. Fortunately, dermatologists have a wealth of knowledge on how to manage and even prevent ...

Stop being ~sluggish~ about your skincare and get some budget-friendly snail mucin in your life. View Entire Post › ...

"The Last of Us" prosthetics designer and costume designer pulled directly from the game to find the right look for the Scars ...

The next generation of skin resurfacing technology will debut at the ASLMS 2025 Conference LAVAL, QC / ACCESS Newswire / April 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, di ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.